Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Decline in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 39,600 shares, a decrease of 43.8% from the February 28th total of 70,400 shares. Currently, 0.4% of the shares of the stock are sold short. Based on an average trading volume of 62,300 shares, the short-interest ratio is currently 0.6 days.

Wall Street Analysts Forecast Growth

Separately, Chardan Capital restated a “buy” rating and set a $10.00 target price on shares of Senti Biosciences in a report on Monday, December 2nd.

Institutional Trading of Senti Biosciences

A hedge fund recently bought a new stake in Senti Biosciences stock. Virtu Financial LLC bought a new position in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 13,356 shares of the company’s stock, valued at approximately $47,000. Virtu Financial LLC owned 0.28% of Senti Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.73% of the company’s stock.

Senti Biosciences Trading Up 3.0 %

NASDAQ:SNTI traded up $0.10 during trading hours on Friday, hitting $3.43. The company had a trading volume of 9,037 shares, compared to its average volume of 784,513. Senti Biosciences has a 1 year low of $1.52 and a 1 year high of $16.94. The company has a market cap of $16.57 million, a P/E ratio of -0.22 and a beta of 2.52. The company has a 50-day moving average of $3.88 and a 200 day moving average of $3.47.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.13) by $2.46. The firm had revenue of $5.86 million during the quarter, compared to analysts’ expectations of $2.80 million. On average, analysts forecast that Senti Biosciences will post -14.54 earnings per share for the current year.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.